Living Meta-Analysis Finds No Clear Pancreatitis Signal for Semaglutide and Tirzepatide in Randomized Trials

Bottom line: Pooled randomized trial data through March 2026 do not confirm that semaglutide or tirzepatide meaningfully increases acute pancreatitis risk — but the question is not definitively closed, and clinical vigilance remains appropriate.

Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin-based therapies that enhance glucose-dependent insulin secretion, suppress glucagon, and reduce appetite. The class includes semaglutide (Ozempic, Wegovy) and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro, Zepbound). A persistent safety concern since early GLP-1 RA development has been whether these drugs increase acute pancreatitis risk.

Study Design

This living systematic review and meta-analysis, posted as a preprint on medRxiv in March 2026, searched Medline and ClinicalTrials.gov for all placebo-controlled randomized trials of semaglutide and tirzepatide reporting acute pancreatitis incidence.¹ The protocol was preregistered (PROSPERO ID 1346039). The primary analysis used a Peto odds ratio method appropriate for rare events.

Key Findings

• No significant risk increase: The pooled analysis across eligible trials found no statistically significant increase in acute pancreatitis with either semaglutide or tirzepatide versus placebo.¹
• Very low event rates: Acute pancreatitis occurred in fewer than 0.5% of participants in both treatment and placebo arms across included studies, limiting statistical power.¹
• Consistent with prior large analyses: These results align with cardiovascular outcome trial safety data from SELECT (semaglutide) and SURPASS/SURMOUNT (tirzepatide) programs, which did not identify pancreatitis as a significant safety signal.
• Living review design: As a living meta-analysis, this will be updated as new trial data emerge, providing an evolving picture of this safety question.

Why It Matters

Pancreatitis concerns have shadowed the GLP-1 RA class since early postmarketing reports with exenatide over a decade ago. While observational studies have sometimes shown modest associations, confounding by obesity and gallstone disease (both pancreatitis risk factors and indications for GLP-1 RA use) complicates interpretation. This review focuses exclusively on randomized data, which are less susceptible to confounding.

The reassurance is welcome given the explosive growth in GLP-1 RA prescribing for both diabetes and obesity. However, the rarity of pancreatitis events means even large meta-analyses may lack power to detect a small absolute risk increase.

For related safety data, see our coverage of tirzepatide GI safety and the GLP-1 RA noncardiometabolic outcomes umbrella review.

Clinical Implication

This meta-analysis provides additional reassurance for prescribers but does not eliminate the need for clinical judgment. Continue screening for pancreatitis history before initiating GLP-1 RAs, counsel patients on warning symptoms (severe epigastric pain radiating to the back), and maintain a low threshold for workup if symptoms arise — especially in patients with gallstones or hypertriglyceridemia.

---

¹ GLP-1 receptor agonists and the risk of acute pancreatitis: a living systematic review and meta-analysis of randomized controlled trials. medRxiv. Posted March 19, 2026. DOI: 10.64898/2026.03.19.26348844v1